Guardian Pharmacy Services, Inc., one of the largest long-term care pharmacy services companies in the U.S., reported a robust first quarter for 2025. The company experienced a revenue increase of 20% year-over-year, totaling $329.3 million, fueled by organic growth and acquisitions, including Heartland Pharmacy and Freedom Pharmacy.

The resident count at the end of March reached approximately 189,000, reflecting a 15% rise compared to the prior year. Gross profit also saw a notable increase, reaching $64.4 million, a 17% uptick from the same period last year. Adjusted EBITDA amounted to $23.4 million, up 16% compared to $20.3 million a year earlier, resulting in an EBITDA margin of 7.1%. When excluding costs related to being a public company, adjusted EBITDA growth is reported at 20%.

For the first quarter, net income was recorded at $9.3 million, a gain of $2.2 million year-over-year. The company concluded the quarter with $14 million in cash and no long-term debt, indicating strong financial health. Looking forward, Guardian Pharmacy maintained its revenue guidance for 2025 in the range of $1.33 billion to $1.35 billion and reiterated adjusted EBITDA guidance between $97 million and $101 million.

This guidance includes the impact of an anticipated $4 million in public company expenses for the full year. Overall, Guardian Pharmacy’s strategic acquisitions and solid operational performance positioned the company well for continued growth in the longer term.